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Abstract 
The analysis of circulating cancer biomarkers in the form of liquid biopsies confers several 
potential benefits as compared to traditional surgical tissue sampling. As a common key 
anomaly strongly implicated across several cancer types, the BRAFV600E mutation is one the 
most valuable oncogenic biomarkers available in liquid biopsies. Crucially, BRAFV600E is also 
an actionable mutation which could be arrested by clinically beneficial drug inhibitors. Yet, as 
is true for most single base disease mutations, current BRAFV600E detection in either its DNA 
or protein molecular state is still liable to false positive/negative outcomes, thus impacting 
patient treatment benefit. Here we present an integrated multi-molecular sensor (IMMS) for an 
entire sample-to-answer workflow from melanoma cell capture to simultaneous quantification 
of both intracellular BRAFV600E DNA and protein levels on a single platform. The IMMS 
combines (i) specific capturing and release of circulating melanoma cells; (ii) electric field-
induced cell lysis; (iii) simultaneous quantification of BRAFV600E DNA and protein levels. We 
investigated the IMMS system’s analytical performance in cell capture, release and lysis; and 
intracellular BRAFV600E detection by ligase-mediated DNA amplification and antibody-based 
protein hybridization. As a proof-of-concept, we successfully demonstrated circulating 
BRAFV600E detection at both DNA and protein molecular levels in simulated melanoma plasma 
samples. With its capabilities in integrated and miniaturized analysis, the IMMS could lead the 
emergence of a new generation of multi-molecular lab-on-chip biosensors for enabling more 
accurate and extensive analysis of powerful circulating biomarkers in patient liquid biopsies.   
Introduction 
Liquid biopsies refer to the non-invasive analysis of cancer mutations, often utilizing 
circulating tumor cells (CTCs) and circulating tumor (ct)DNA in patient biofluid samples such 
as blood, urine or saliva.1, 2 The main motivation of using liquid biopsies is the potential to 
overcome shortcomings associated with tissue biopsy, such as i) surgical invasiveness; ii) 
limited small area evaluation of tumor at a single timepoint; iii) failure to represent complex, 
heterogeneous, and constantly-evolving tumor microenvironment. Most importantly, several 
recent groundbreaking studies have demonstrated the feasibility of using liquid biopsies as a 
possible tissue surrogate for detecting notable oncogenic aberrations, including circulating 
single point mutations in BRAF.1, 3-6 
 BRAF encodes for a Raf kinase protein that is involved in cell growth signalling, and 
has been shown to be frequently mutated in cancers, including malignant melanoma, colorectal 
cancer, and non-small-cell lung carcinoma.7, 8 The majority of BRAF single point mutations 
consist of a single T→A base change at nucleotide 1799, resulting in an amino acid change of 
valine to glutamate in the encoded protein (now termed as “V600E”). The BRAFV600E mutation 
is a valuable prognostic and predictive biomarker that is presently implemented in the clinic 
for late-stage malignant melanoma. Critically, BRAFV600E is also a clinically-actionable 
aberration with the administration of BRAF inhibitors such as FDA-approved drugs: verufenib 
and debrafenib.9, 10 Therefore, molecular analysis of circulating BRAFV600E in liquid biopsies 
is of great clinical interest in both non-invasive cancer screening and drug response monitoring.  
 Over the past years, there have been a variety of developed techniques for molecular 
BRAFV600E analysis in DNA or protein forms.11-13 For molecular BRAFV600E detection on the 
DNA level, a variety of techniques including Sanger sequencing, pyrosequencing, and PCR-
based assays have been demonstrated with exceptional detection sensitivity. Yet, as is true for 
all single base disease mutations, DNA-based BRAFV600E detection faces poor detection 
specificity due to cross-reactivity with highly similar wildtype/other V600 mutation 
sequences.14  More recently, the emergence of mutation-specific monoclonal antibodies has 
enabled BRAFV600E detection on the protein level. Although showing 100% detection 
specificity, protein-based BRAFV600E analysis is still liable to false negatives due to insufficient 
sensitivity. Hence, this has led to a potential concept of combining protein- and DNA-based 
BRAFV600E detection,15 in order to increase the accuracy of BRAFV600E testing with both 
superior detection sensitivity and specificity. Ideally, this could serve as a useful cross-
verification tool for circulating BRAFV600E status in individual patients, especially if combined 
DNA and protein detection are achievable simultaneously at reduced assay time. To address 
this need, we were thus motivated to develop a single biosensing platform which is capable of 
the difficult task of simultaneously detecting both circulating BRAFV600E DNA and protein in 
liquid biopsies.     
Microfluidic biosensors are ideal for merging both DNA and protein detection 
techniques due to the possibility of miniaturizing laboratory-based bioassays onto a single 
device platform.16 Apart from the distinct advantages of minimal liquid sample requirement, 
rapid bioassay analysis, and potential point-of-care use; microfluidic biosensors also enable 
integration of all sample preparation, target amplification, and detection readout to realize lab-
on-a-chip applications. Microfluidic sensors are therefore an attractive option for conceiving 
an integrated platform capable of combined BRAFV600E DNA and protein analysis for potential 
clinical liquid biopsy utilization.   
Herein, we developed a novel integrated multi-molecular sensor (IMMS) for the 
combined analysis of BRAFV600E in melanoma cells at both DNA and protein levels. 
Specifically, the IMMS platform consists of individual microfluidic zones with customized 
electrode patterns in microchambers for i) specific capturing and release of melanoma cells via 
melanoma-associated chondroitin sulfate proteoglycan (MCSP) expression; ii) electric field-
induced cell lysis; iii) selective ligase-mediated amplification and antibody-based 
hybridization of intracellular BRAFV600E DNA and protein targets respectively; and iv) eventual 
electrode-based electrochemical readouts of BRAFV600E DNA and protein levels. It is envisaged 
our described IMMS platform could allow more reliable circulating biomarker testing in liquid 
biopsies by interrogating the same mutation status in differing DNA/protein molecular forms.  
 
Materials and methods 
Materials 
All reagents (Sigma Aldrich, Australia) were of analytical grade and used without further 
purification unless otherwise stated. UltraPureTM DNase/RNase-free distilled water 
(Invitrogen, Australia) was used throughout the experiments. Oligonucleotides (Integrated 
DNA Technologies, Singapore) sequences used in this work are shown in Table S1. 
 
IMMS design and fabrication 
The IMMS design consists of cell capture and release; lysis; and combined detection 
microfluidic zones. The zone for capture and release has a long serpentine microchannel with 
an array of 264 parallel electrode pairs (electrode size: 100 μm (d1) and 400 μm (d2), distance 
between electrodes within pairs: 50 μm and between pairs: 150 μm) along the channel length. 
The lysis zone contains a pair of square symmetric electrodes (2 mm) within a proximity of 3 
mm.  
The combined DNA and protein detection zone contains three sets of circular working 
(1000 μm in diameter) and 120 μm thick ring electrode pairs. Both circular and ring electrodes 
are connected separately to a pair of common connection pads, and the inner circular and ring 
electrode are separated by 1000 μm. 
The IMMS was fabricated following standard photolithography procedure at Australian 
National Fabrication Facility-Queensland Node.  Initially, the IMMS design was prepared 
using L-Edit V15 (Tanner Research, USA) and translated to photomask by direct laser writer.  
Then the design in the photomask UV exposed to a thin AZ nLOF 2070 negative photoresist 
(MicroChemicals, Germany) coated silicon wafer. After hard baking at 110 ºC for 2 min, 
design was revealed by dipping the wafer in AZ 726 developer (MicroChemicals, Germany) 
for 2 min. The wafers were then loaded to a Temescal FC-2000 electron beam evaporator 
(Ferrotec, USA) machine for the layer by layer deposition of Ti (10 nm) and Au (200 nm) and 
after exposure, left in ethanol overnight for lift-off. 
The photomask for microfluidic channel, lysis and protein detection chamber was UV 
exposed at 380 mJ/cm2 to a silicon wafer coated with 1 mm negative SU-8 215 photoresist 
layer and hard baked on hot plate (from 65 °C for 5 min, 95 °C for 20 min, 65 °C for 3 min). 
Following that, wafers were kept in propylene glycol methyl ether acetate (PGMEA) solution 
for 45 min and then cleaned with 2-isopropanol solution to reveal the structure. After that, 
prepolymer was mixed with its cross-linker Sylgard 184 (Dow Corning, USA) in a ratio of 
10:1, and poured on the newly prepared SU8 master mould for incubation at 65 ˚C for 1 h. An 
individual PDMS layer was then placed on the gold-patterned silicon wafer to complete the 
IMMS fabrication. 
 
Cell culture 
SK-MEL-28, SK-MEL-35, SKBR3 and MD-MBA-231 were cultured in RPMI 1640 growth 
media supplemented with fetal bovine serum (10%), glutamax (1%) and 
penicillin/streptomycin (Thermo Fisher Scientific, Australia) in a 37° C, 5% CO2 incubator. 
Culture media was changed every third day and cells were harvested upon 80% confluences in 
the culture flask. Prior to imaging experiments, the membranes of harvested cells were stained 
by incubating with DiO (3,3'-Dioctadecyloxacarbocyanine Perchlorate) fluorescence dye 
(Invitrogen, UK) at 37 ˚ C for 10 min (5 µL of DiO dye for 100 000 cells/sample). Post-staining, 
labeled cells were washed three times with phosphate buffer saline (PBS) by centrifuging at 
300 g for 5 min and resuspended in 1 mM PBS solution. 
 
IMMS cell capture, release, and lysis 
The microchannel of the capture and release microfluidic zone was modified with anti-MCSP 
antibodies following layer by layer functionalization processes. For antibody functionalization, 
250 µL of 200 µg/mL of biotinylated bovine serum albumin (Thermo Fisher Scientific, 
Australia) was added to the bare surface of the microchannel and incubated for 2 h at 37 ˚C. 
Then, the surface modified microchannel was washed gently to remove unbound molecules 
and subsequently incubated for another 1 h at 37 ˚C with a solution of 100 µg/mL streptavidin 
in PBS, Invitrogen). In a final step, biotinylated anti-MCSP antibodies (Invitrogen, Australia) 
were hybridized onto the streptavidin coated surface by incubation for 1 h at 37 ˚C. A signal 
generator (Agilent Technologies 33510B, USA) was used for all subsequent on-chip workflow 
steps which required current field generation.   
For general cell capture experiments, designated number of SK-MEL-28 cells were 
prepared in 1 mM PBS to 200 µL and flown through the anti-MCSP functionalized 
microchannel using an optimal alternating current (ac) field17 (frequency (f) = 600 Hz, 
amplitude (Vpp) = 100 mV). For cell capture experiments using simulated patient plasma 
samples, designated number of target cells were reconstituted in healthy human plasma (200 
µL) and driven through anti-MCSP functionalized device under optimal ac-EHD field (f = 600 
Hz, Vpp = 100 mV). Then, the microchannel was gently washed with 1 mM PBS to remove 
unbound and/or non-specifically adsorbed molecules.  
For fluorescence cell imaging and enumeration experiments, captured cells were 
initially fixed by filling the microchannel with cold methanol for 10 min, and then 
permeabilized by filling the microchannel with 0.2% Triton X-100 in PBS for 10 min. After 
permeabilization, fixed SK-MEL-28 cells were nuclear-stained with 4′,6-diamidino-2-
phenylindole (DAPI) solution for 15 min. Following this step, the microchannel was gently 
washed with 1 mM PBS solution to remove excess DAPI solution. Finally, DiO- and DAPI-
stained captured cells were imaged and enumerated with a multichannel fluorescence 
microscope (Nikon Ti−U, USA). Captured melanoma cells were then released using a direct 
current (dc) field as previously described.17 
For cell lysis and release of intracellular contents, captured and released melanoma cells 
were transferred to the lysis microfluidic zone. The application of dc electric potential produced 
a strong electric field required to disrupt the transmembrane of cells for lysis.18, 19 Under an 
optimal dc potential of 5 V as latterly described, cells were lyzed and their internal molecular 
contents were released for downstream BRAFV600E DNA and protein analysis.  
 
IMMS BRAFV600E DNA detection 
The detection of BRAFV600E DNA on the IMMS was started in a ligation microchamber of the 
detection microfluidic zone. An aliquot of cell lysate from the lysis microfluidic zone was first 
magnetically purified for nucleic acids within the microchamber by using the Agencourt 
AMPure XP SPRI kit (Beckman Coulter, USA) according to manufacturer’s instructions and 
placing a permanent magnet below the microchamber. 
The isolated nucleic acids were resuspended in 5 μL RNase-free water, and then 
transferred into the ligation microchamber to make up a 10 μL ligation mixture containing 100 
nM of each ligation probe (each with unique primer recognition site), 40 U T4 DNA Ligase 
(New England Biolabs, Australia) and 1x T4 DNA Ligase Buffer. The mixture was heated to 
95 °C for 3 min by placing the IMMS on a heating block, and then left to cool down to room 
temperature for 15 min to facilitate hybridization and ligation20 under alternating current-
electrohydrodynamic (ac-EHD) fluidic mixing (f = 500 Hz, Vpp = 800 mV).  
Before isothermal recombinase polymerase amplification (RPA)16, 21 on magnetic bead 
surfaces, primer functionalized magnetic beads were prepared beforehand. 10 µL of 
streptavidin-labeled magnetic beads (New England Biolabs, Australia) was first washed with 
2× washing and binding (B&W) buffer (10 mM Tris-HCl, pH 7.5; 1 mM EDTA; 2 M NaCl) 
and resuspended in 25 μL of 2x B&W buffer. Then, the resuspended magnetic bead surfaces 
were functionalized by thorough mixing and incubation with 5 µM biotinylated forward primer 
sequences (Table S1) on a mixer for 30 min at room temperature. After surface 
functionalization, excess unbound primers were removed by magnetic washing with 2x B&W 
buffer thrice, and functionalized magnetic beads were resuspended in 5 µL RNase-free water.  
For solid-phase RPA in the amplification microchamber, the TwistAmp® Liquid Basic 
kit (Twist-DX, UK) was used with slight modifications to manufacturer’s instructions. Briefly, 
12.5 μL of 2x Reaction Buffer, 1.8 mM dNTPs, 20 nM biotinylated dUTPs (Thermo Fisher 
Scientific, Australia), 2.5 μL 10x Basic E-mix, and 500 nM of reverse primers (Table S1) were 
added to the amplification microchamber, and mixed via ac-EHD for 30 s to make a pre-master 
mix volume of 22 µL. Next, 1.25 20x Core Reaction Mix was added and mixed via ac-EHD 
for 30 s; before 5 µL of pre-functionalized magnetic beads, 1.25 μL 280mM MgOAc, and 1 
μL ligation mixture (from the ligation microchamber) were added to the amplification 
microchamber for incubation at 43°C for 15 min. During solid-phase RPA, ac-EHD fluidic 
mixing was induced through application of an ac field (f = 800 Hz and Vpp = 800 mV) to 
enhance molecular reaction kinetics.  
Post-amplification, the magnetic beads were washed with 2x B&W buffer as described 
before, incubated with 1 µL 1:1000 diluted streptavidin-horse radish peroxidase (HRP) in 10 
mM PBS with 0.5% triton-X for 5 min to label bead surface-bound amplicons, and washed 
again before being magnetically loaded onto the working electrode surface of the 
microchamber. For amperometric measurements, 15 µL of 1-Step™ TMB (3,3',5,5'-
Tetramethylbenzidine) solution (Thermo Fisher Scientific, Australia) was added to the surface-
loaded magnetic beads before 500 mM H2SO4 was added after 5 min to stop the reaction and 
activate TMB for measurements. Amperometric measurements were carried out using a 
CHI650D electrochemical workstation (CH Instruments, USA) at 150 mV, 30 s. All 
measurements were performed at room temperature. 
 
IMMS BRAFV600E protein detection 
Prior to the electrochemical BRAFV600E protein measurements, the gold electrode in the protein 
detection domain of the IMMS was functionalized with BRAFV600E antibodies using biotin-
streptavidin chemistry (Fig. S1). In brief, the following solutions were incubated in the 
following order: 2 ng/mL biotinylated bovine serum albumin (Pierce Biotechnology, USA) for 
2 h, 1 ng/mL streptavidin (Sigma Aldrich, Australia) for 1 h, 0.1 µM 6-mercapto-1-hexanol 
(Sigma Aldrich, Australia) for 10 min, and 0.1 ng/mL monoclonal BRAFV600E ab200535 
(Abcam, Australia) for 1 h. To remove excess reagents, the electrode was washed after each 
incubation step with 10 mM PBS.  
After functionalization, an aliquot of cell lysate (diluted to the required concentration 
in 10 mM PBS) from the lysis microfluidic zone was transferred onto the functionalized 
electrode and subjected to ac-EHD fluidic mixing frequency (f = 500 Hz, Vpp = 800 mV) for 3 
min to promote the movement of protein molecules to the electrode surface as reported 
previously.22 After fluidic mixing, the electrode was washed with PBS and DPV measurements 
were performed using ferri/ferrocyanide redox couple (i.e., 2.5 mM [Fe(CN)6]
3- / [Fe(CN)6]
4- 
(1:1) and 0.1 M KCl in 10 mM phosphate buffered saline at pH 7.4) with a CHI650D 
electrochemical workstation (CH Instruments, USA). The DPV measurements were recorded 
from -1.0-1.0 V with a pulse amplitude of 50 mV, a pulse width of 50 ms, a potential step of 5 
mV, and a pulse period of 100 ms. The peak intensity of the DPV signal before (ibefore) and 
after (iafter) target incubation was used to calculate the relative current change (%ir) as given by 
%ir = [(ibefore – iafter)/ibefore] x 100%.  
 Results and discussion 
IMMS platform for combined BRAFV600E DNA and protein analysis 
The IMMS platform has three independent microfluidic zones for 1) cell capture and release; 
2) cell lysis to release intracellular content; and 3) combined detection of BRAFV600E DNA and 
protein targets (Fig. 1). Previously, our research group has described the use of asymmetrical 
electrode design on microfluidic devices to generate an ac-EHD fluid flow for diverse 
biomolecular applications.22-25 Here, we exploited various miniaturized electrode designs on 
our IMMS platform to manipulate fluidic movement of biomolecules at several steps along the 
IMMS workflow to enable on-chip sample-to-DNA/protein detection. 
The cell capture and release microfluidic zone consists of a serpentine microchannel 
with an array of 264 parallel asymmetric gold electrode pairs. The electrodes are pre-
functionalized with anti-MCSP antibodies for selective capture of BRAFV600E-positive 
melanoma cells under an ac-EHD effect. This facilitates unidirectional sample flow through 
the functionalized microchannel without any external pump, and assists the removal of non-
specifically adsorbed molecules (Fig. 1a). After cell capturing and washing, a reductive dc 
potential is applied across the electrode array to break anti-MCSP antibody-electrode surface 
thiol bonds. This dc potential releases the captured melanoma cells for transfer to the cell lysis 
zone.  
The lysis zone has a pair of symmetric square electrodes to induce an electric field for 
lysis of released cells (Fig. 1b). The application of a dc electric potential across the square 
electrodes disrupt and rupture the cellular membranes, allowing intracellular contents 
(including nucleic acids and proteins) for downstream BRAFV600E analysis. The combined 
BRAFV600E detection zone consists of a series of microchambers with each containing an 
identical asymmetrical circular and ring electrode pair, and is designed to simultaneously detect 
BRAFV600E DNA and protein targets from the intracellular contents of lyzed melanoma cells 
(Fig. 1c).  
For BRAFV600E DNA detection (Fig. 1c-i), an aliquot of cell lysate is first magnetically 
purified on the IMMS for nucleic acids. Then, BRAFV600E ligation probes (with unique primer 
recognition sites) are added for complementary binding to purified BRAFV600E DNA, and 
successfully bound probes are subsequently ligated by T4 DNA ligases. A fraction of ligated 
probes is then transferred to a separate amplification microchamber containing primer 
functionalized magnetic beads for solid-phase isothermal RPA. Importantly, we use the 
asymmetrical circular and ring electrode design on the IMMS for ac-EHD fluidic mixing to 
increase molecular kinetics during both solution-based ligation and solid surface-based 
amplification processes. After amplification, bead surface-bound amplicons are tagged with 
streptavidin-HRP enzymes through randomly-inserted biotin-uracil bases during 
amplification.26 The magnetic beads with bound amplicons are then washed and concentrated 
onto the electrode sensor surface by use of a permanent magnet. The addition of TMB 
chromogenic electron mediators gives rise to a HRP-catalyzed amperometric current signal to 
reflect initial BRAFV600E DNA quantity.   
For BRAFV600E protein detection (Fig. 1c-ii), we introduce cell lysate onto a electrode 
surface which is pre-functionalized with anti-BRAFV600E capture antibodies. We monitored the 
stepwise functionalization using differential pulse voltammetry (DPV) whereby each 
successful stepwise functionalization resulted in a further decrease in DPV current (Fig. S1) 
due to increased retardation of redox reaction on the electrode surface. For target capture, ac-
EHD fluidic mixing is likewise performed to promote BRAFV600E protein target movement 
towards the sensor surface. After target capture and washing, a [Fe(CN)6]
3−/4− redox system is 
used to generate a detectable Faradaic current signal that corresponds to initial BRAFV600E 
protein level.  
 
IMMS melanoma cell capture and release 
A key aspect of the IMMS is its capacity to perform the entire sample-to-answer workflow on 
a single platform. This process starts with the specific capture of melanoma cells for 
downstream BRAFV600E DNA and protein analysis. We first tested the melanoma cell capture 
efficiency on the IMMS by flowing various PBS-diluted amounts of SK-MEL-28 melanoma 
cells (50, 100, 250, 500, 1000 cells) through the anti-MCSP functionalized microchannel under 
an ac-EHD-driven flow, and enumerated the DiO- and DAPI-stained captured cells via 
fluorescence microscopy (Fig. 2a). Under the applied electric field, the average capture 
efficiencies for SK-MEL-28 cells (Fig. S2) were consistent for different cell count: 82.0±3.46% 
(50 cells), 81.0±1.73% (100 cells), 82.6±0.93% (250 cells), 81.6±1.58% (500 cells) and 
85.4±0.83% (1000 cells). Next, to replicate cellular heterogeneity in patient blood samples, we 
mixed SK-MEL-28 target cells with a high background of 106 peripheral blood mononuclear 
cells (PBMCs) to further evaluate capture efficiency in a biologically-complex environment. 
For these mixed samples, we noticed an expected slight ~10% decrease in capture efficiency 
which was consistent for different amounts of SK-MEL-28 cells: 72.66±1.76% (50 cells), 
70.33±1.45% (100 cells), 71.20±0.61% (250 cells), 71.66±0.81% (500 cells) and 74.7±0.61% 
(1000 cells) (Fig. 2b). This level of capture efficiency is similar to our previous report on 
specific capturing of breast cancer cells.17 Hence, we demonstrated consistent capturing 
efficiency at differing amount of melanoma cells. CTC counts in blood could range from 10-
100 cells/mL,27 we thus reasoned that our proposed IMMS could be feasible for liquid biopsy 
applications by relying on a rapid external pump-free ac-EHD-driven flow through the 
microchannel to capture a clinically-relevant amount of cancer cells.   
Next, we investigated the capture specificity in the anti-MCSP functionalized 
microchannel by driving 106 pre-stained MCSP-negative breast cancer cells (SKBR-3 and MD-
MBA-231) through the anti-MCSP functionalized microchannel. We observed low capture rate 
(Fig. 2c) for both non-specific cell lines to verify minimal nonspecific cell adsorption within 
the microchannel.  
It is essential to release captured melanoma cells for downstream cell lysis and analysis 
of intracellular contents on the IMMS. To evaluate the release efficiency of captured cells 
through the application of an applied dc potential, we quantified released cells for comparison 
against starting cell count. A consistent release efficiency of 89.38±0.48% was established for 
each different starting cell amount (Fig. 2d) to demonstrate substantial cell release performance 
for downstream analysis.  
To further investigate the capability of IMMS for isolating target cells in liquid 
biopsies, the capture and release efficiency in diluted blood was studied. We titrated 100 SK-
MEL-28 cells in diluted human blood (i.e. 10-fold dilution in 1 mM PBS) and performed 
capture experiments with and without ac-EHD (pressure driven flow, flow rate = 8.3 µL min-
1). Under ac-EHD conditions (f = 600 Hz and Vpp = 100 mV), the average capture efficiency 
was recorded at 69±1.73% (Fig. S3) as similar to cell capture experiments from simulated 
plasma samples and approximately 18% higher than cell capture efficiency from the blood 
sample without ac-EHD. We also tested release efficiency of the isolated cells under optimized 
DC field and found similar cell retrieval efficiency (approximately 89% for cells isolated from 
diluted blood sample). These data demonstrate that IMMS is potentially suitable for cellular 
and molecular detection from complex heterogeneous samples. 
 
IMMS cell lysis optimization 
Efficient cell lysis requires the generation of an optimal electric field for rupturing the cell 
membrane. An insufficient dc potential cannot disrupt the cell membrane bilayer effectively 
for lysis, and an excessive electric potential can damage the electrodes in use.18, 19  We 
optimized the applied potential on the IMMS platform for efficient lysis of captured and 
released SK-MEL-28 cells. To evaluate the optimal applied dc potential, we first engaged a 
range of dc potential from 3-5 V for 6 min, and observed the number of unlyzed cells through 
the fluorescence microscope (Fig. 3a). At 3V, cell lysis efficiency was poor with only 
40.63±0.96% of lyzed but improved to 93.36±0.59% with increased applied potential up to 5 
V. Beyond 5 V, cell lysis efficiency did not show significant increase and the resultant high 
current started to damage the cell lysis electrodes on the IMMS. We thus opted to use 5 V for 
the ensuing optimization of electric field duration. We found that 4 min of applied dc potential 
led to 93.23±1.16% of lyzed cells in the lysis zone (Fig. 3b), and no advancement in lysis 
efficiency was noted with longer durations. Therefore we chose to apply a dc potential of 5V 
potential for 4 min for efficient electrical lysis (Fig. 3c) of captured and released melanoma 
cells. 
 
IMMS detection specificity 
Specific BRAFV600E detection is crucial for accurately informing mutation status and 
subsequent clinical decisions. To ensure high accuracy of combined BRAFV600E DNA and 
protein detection on the IMMS platform, we evaluated the detection specificities of probes and 
antibodies on cultured cells with known BRAFV600E expression status: two melanoma 
(BRAFV600E-positive SK-MEL-28 and BRAFV600E-negative LM-MEL-35) and one breast cancer 
(BRAFV600E-negative SKBR3) cell lines. Each cell line underwent capture, release and lysis 
procedures on the IMMS platform before integrated downstream BRAFV600E analysis.  
On the DNA level, BRAFV600E detection is often compounded by specificity issues as 
oligonucleotide primers/probes tend to cross-react with wildtype/other V600 mutation DNA in 
the background. To improve BRAFV600E DNA detection specificity, we utilized the IMMS to 
perform a T4 DNA ligase-mediated ligation of BRAFV600E-specific probes prior to isothermal 
solid-phase RPA of the ligated probes on magnetic beads. This dual target-specific ligation and 
RPA steps ensured selective BRAFV600E detection (Fig. 4a) as T4 DNA ligase confers the ability 
of single base discrimination to ligate probes in target presence, whilst RPA occurs only for 
successfully ligated probes.20 It is noteworthy that both ligation and RPA molecular kinetics 
were enhanced by ac-EHD fluidic mixing instead of relying on slow diffusion kinetics.24 We 
demonstrated enhanced detection specificity toward BRAFV600E-positive SK-MEL-28 with 
eight-fold higher amperometric signals (Fig. 4b) as compared to BRAFV600E-negative LM-
MEL-35 and SKBR3. These findings were successfully validated with previously-reported cell 
line BRAFV600E characterization results,28 and standard gel electrophoresis (data not shown) in 
which successful BRAFV600E amplification was observed for SK-MEL-28 with BRAFV600E PCR 
primers (Table S1). 
On the protein level, we evaluated the BRAFV600E detection specificity of the anti-
BRAFV600E capture antibodies used in our study. We first investigated the possibility of non-
specific BRAFV600E adsorption on the sensor surface by performing several control experiments 
in absence of anti-BRAFV600E capture antibodies and BRAFV600E protein targets, as well as in 
presence of non-target wildtype BRAF proteins and non-target anti-CD63 capture antibodies. 
The presence of BRAFV600E-specific antibodies and targets generated a five-fold higher relative 
current change than the controls (Fig. 4c), thus demonstrating that high signal was achieved by 
specific capturing of target protein through sensor surface functionalized antibodies. Notably, 
the functionalized asymmetrical electrode format was also able to be engaged for ac-EHD 
fluidic mixing, thereby resolving the slow diffusion of protein targets towards the sensor 
surface. Furthermore, as similar to the DNA analysis, we also found that BRAFV600E protein 
detection was highly specific for SK-MEL-28 and resulted in a four-fold relative current 
change in contrast to BRAFV600E-negative cell lysates (Fig. 4d) which contained a high 
abundance of non-target cell debris. This suite of experiments showed that BRAFV600E protein 
detection with excellent specificity was obtained through effective capture antibody-
functionalized sensor surface on the IMMS platform.  
 
IMMS detection sensitivity 
BRAFV600E DNA detection requires high detection sensitivity for early disease detection and 
need to discriminate low copy amounts of BRAFV600E in presence of high wildtype background. 
We opted to use a magnetic bead-based enrichment strategy to load amplicons carrying HRP 
molecules onto the electrode surface and concentrate the amperometric signal sources for 
enhanced sensitivity. To evaluate detection sensitivity on the DNA level, we prepared a dilution 
series (0-100%) of BRAFV600E sequences in a background of wildtype BRAF sequences (10 000 
copies in total) (Fig. 5a). To simulate the biological complexity of patient-derived samples, we 
further included 5 ng of salmon sperm DNA into each preparation. With this experimental 
construct, we detected as low as 0.1% (10 copies) of mutant BRAFV600E sequences (Fig. 5b).  
To assess BRAFV600E protein detection sensitivity, we first sought to investigate the 
sensitivity and dynamic range of BRAFV600E protein in buffer to establish the conditions for 
subsequent cell lysate detection. The IMMS platform detected as low as 10 pg/mL of 
BRAFV600E protein (Fig. 5c), and showed a dynamic response from 0-100 pg/mL. We then 
analyzed cellular lysate from a range of SK-MEL-28 cell concentration (0-100 cells/mL). A 
gradual increase in relative current change associated with BRAFV600E levels was observed with 
increasing cell concentration, and the platform was capable of BRAFV600E protein detection 
from a prepared lysate concentration of 10 cells/mL (Fig. 5d).  
Altogether, these results demonstrated that our IMMS platform is capable of clinically-
relevant amounts of circulating BRAFV600E DNA and protein biomarker detection for potential 
liquid biopsy applications.27 
 
Combined BRAFV600E quantification in simulated patient liquid biopsies  
After extensive analytical performance testing of the IMMS as described above, the rational 
final step is to investigate its designed use for combined circulating BRAFV600E quantification 
in clinical samples. To evaluate the feasibility of the IMMS platform for patient liquid biopsy 
applications, we performed the whole IMMS workflow on simulated plasma samples. To this 
end, we prepared known concentrations (25, 50, 100 cells/mL) of SK-MEL-28 cells in 
BRAFV600E-negative healthy human plasma samples, and started with melanoma cell capture 
to eventual analysis of BRAFV600E DNA and protein levels on the IMMS. The IMMS was able 
to quantify BRAFV600E at both DNA (Fig. 6a) and protein (Fig. 6b) levels of different cell counts 
in the simulated plasma samples. This outcome is highly encouraging as a key indication that 
our IMMS is suitable as a lab-on-chip platform for processing raw clinical samples without 
off-chip purification. Pointedly, the capture and release microfluidic zone is robust in specific 
capturing of SK-MEL-28 melanoma cells from a biologically-complex matrix of biomolecules 
present in unprocessed plasma. This allowed for accurate downstream analysis as observed 
from the quantitative BRAFV600E DNA and protein detection. The IMMS also demonstrated 
high detection reproducibility as %RSD values for DNA (13.3, 8.6, and 5.9%) and protein 
(10.9, 11.2, and 8.9%) detection in 25, 50, and 100 cells. From a clinical perspective, the IMMS 
could be of use in quantifying mutational burden for treatment decision-making or monitoring 
BRAFV600E levels to evaluate treatment efficacy.  
 Finally, we also observed a strong correlation (Pearson correlation coefficient = 0.98) 
between matching BRAFV600E DNA and protein expression levels in the same simulated plasma 
sample (Fig. 6c) on our single IMMS platform. This observation reinforced the concept of 
using simultaneous combined BRAFV600E DNA and protein quantification to reduce false 
detection outcomes via analysis of a single BRAFV600E molecular form. In addition, as concerns 
still currently persist about the accuracy of liquid biopsy testing (as compared to tissue 
sampling), the ability for BRAFV600E quantification at both DNA and protein levels on the 
IMMS may also serve to provide better-validated interrogation of circulating BRAFV600E status 
in liquid biopsies.   
 Conclusions 
We have demonstrated an IMMS for simultaneous molecular analysis of a clinically actionable 
circulating cancer biomarker, BRAFV600E, at both DNA and protein levels. Through tailored 
electrode design, we successfully achieved an entire sample-to-answer protocol encompassing 
melanoma cell capture in sample source, on-chip cell lysis, and combined quantification of 
intracellular BRAFV600E DNA and protein amounts on a single miniaturized platform. It is 
noteworthy that the IMMS’s detection performance is shown to be highly feasible for 
circulating biomarker analysis in liquid biopsies, notably for the challenging BRAFV600E single 
base mutation which demand highly accurate and sensitive detection techniques for effective 
therapeutic actions.  
As current cancer detection strategies mostly focused on biomarker detection at only a 
sole molecular level (eg. DNA, RNA or protein), we envisioned that our novel IMMS could 
lead the emergence of a new generation of biosensors which uniquely provide combined 
molecular analyses. The main advantages of such combined analyses on a single miniaturized 
platform are (i) cross-validation of a single oncogenic mutation by its different molecular forms 
for enhanced diagnostic accuracy; (ii) comprehensive simultaneous analysis of a panel of 
different biomarkers spanning across DNA/RNA/protein molecular forms to allow “multi-
omic” testing for precision care.    
Beyond the comprehensive proof-of-concept work in this paper for BRAFV600E 
detection, the IMMS is amenable to advancements such as further sensor surface 
miniaturization and scale-up for high-throughput combined detection of more clinically useful 
circulating cancer biomarkers in liquid biopsies. Therefore, we believe that our proposed 
IMMS platform may find its potential in the in-depth analysis of rare tumor biomarkers in 
different molecular forms, thereby enabling better disease progression understanding and/or 
therapeutic decision making. 
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Figure Captions 
 
Fig. 1 Overview of the IMMS platform. (a) Specific melanoma cell capture on anti-MCSP 
functionalized microfluidic zone under ac-EHD and subsequent release of captured cells by 
applied dc potential. (b) Electrical lysis of released cells under dc potential. (c-i) BRAFV600E 
DNA is targeted by mutant-specific ligation probes which are enzymatically ligated upon 
hybridization under ac-EHD fluidic mixing. The successfully ligated probes are then captured 
onto primer functionalized magnetic beads and isothermally amplified under fluidic mixing to 
enhance amplification molecular kinetics. Lastly, the surface-bound amplicons are then 
labelled with HRP enzymes before being magnetically loaded onto the electrode surface for 
amperometric detection. (c-ii) Cell lysate containing BRAFV600E proteins is incubated on an 
anti-BRAFV600E functionalized electrode under ac-EHD fluidic mixing. After target capture, the 
electrode is washed and the BRAFV600E proteins are detected by voltammetry with a 
ferri/ferrocyanide redox couple.         
 
Fig. 2 Melanoma cell capture and release performance on the IMMS platform. (a) 
Representative fluorescence cell images of captured SK-MEL-28 cells: (left) DiO stained cell 
membranes and (right) DAPI stained cell nuclei. Scale bar 10µm.  (b) Capture efficiencies of 
different SK-MEL-28 cell counts in healthy plasma. (c) Capture efficiencies of non-target cells. 
(d) Release efficiencies of captured SK-MEL-28 cells under applied dc potential. Error bars 
represent standard deviation of three independent experiments. 
 
Fig. 3 Optimization of IMMS electrical cell lysis. Cell lysis efficiencies (a) under different 
applied dc potentials, and (b) for different time durations. (c) Representative images of single 
SK-MEL-28 cell before (left) and after (right) electrical cell lysis. Scale bar 20µm. Error bars 
represent standard deviation of three independent experiments. 
 
Fig. 4 IMMS BRAFV600E DNA and protein detection specificities. (a) HRP-catalyzed 
amperometric BRAFV600E DNA signals for BRAFV600E-postive SK-MEL-28, and BRAFV600E-
negative LM-MEL-35 and SKBR3 cell lines. (b) Corresponding average current levels 
reflecting cell line BRAFV600E DNA quantities. (c) Average %ir obtained from positive capture 
antibody-specific target protein capture (anti-BRAFV600E, blue); and negative controls without 
target protein (no BRAFV600E, red), without capture antibody (no anti-BRAFV600E, green), non-
target protein (wildtype BRAF, purple), non-target capture antibody (anti-CD63, orange). (d) 
Average %ir for BRAF
V600E protein detection in SK-MEL-28, LM-MEL-35 and SKBR3 cell 
lines. Error bars represent standard deviation of three independent experiments. 
 
Fig. 5 IMMS BRAFV600E DNA and protein detection sensitivities. (a) HRP-catalyzed 
amperometric BRAFV600E DNA signals for a dilution series (0-100%) of BRAFV600E sequences 
in a background of wildtype BRAF sequences (10 000 copies in total). (b) Corresponding 
average current levels reflecting BRAFV600E DNA quantification. Average %ir obtained for the 
detection of (c) designated BRAFV600E protein concentrations in buffer, and (d) cell lysates of 
BRAFV600E-positive SK-MEL-28 cells. Error bars represent standard deviation of three 
independent experiments. 
 
Fig. 6 IMMS Combined BRAFV600E quantification using simulated patient plasma samples. (a) 
BRAFV600E DNA and (b) protein quantification of known concentrations (25, 50, 100 cells/mL) 
of SK-MEL-28 cells in BRAFV600E-negative human plasma samples. (c) Correlation plot 
showing concordance between matching BRAFV600E DNA and protein expression levels. Error 
bars represent standard deviation of three independent experiments. 
 
